Anixa Biosciences, Inc. (ANIX) News

Anixa Biosciences, Inc. (ANIX): $2.48

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Filter ANIX News Items

ANIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ANIX News Highlights

  • For ANIX, its 30 day story count is now at 4.
  • Over the past 8 days, the trend for ANIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ANIX are CRSP and JPM.

Latest ANIX News From Around the Web

Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.

Anixa Biosciences to Present at Biotech Showcase 2024

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P. Morgan Healthcare Conference ("JPM Week 2024").

Yahoo | December 14, 2023

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

Some of the most explosive opportunities can be found in biotech stocks.

Ian Cooper on InvestorPlace | December 11, 2023

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.

Yahoo | December 6, 2023

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.

Yahoo | December 6, 2023

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."

Yahoo | November 27, 2023

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

Yahoo | November 17, 2023

Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia

Ardelyx (ARDX) announces that the FDA has granted orphan drug designation to Xphozah for the treatment of pediatric hyperphosphatemia. The stock rises 4%.

Yahoo | November 17, 2023

Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates

Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.

Yahoo | November 15, 2023

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.

Yahoo | November 14, 2023

Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus

Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Yahoo | November 10, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!